Universal influenza vaccines: a realistic option?

Clinical Microbiology and Infection

Volumn 22, Issue , 2016, Pages S120-S124

  de Vries, R D ^a   Altenburg, A F ^a   Rimmelzwaan, G F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies; Immunity; Influenza; T lymphocytes; Universal vaccine; Virus vectors

Indexed keywords

CROSS REACTING ANTIBODY; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANTIGEN ANTIBODY REACTION; ARTICLE; CELLULAR IMMUNITY; CROSS PROTECTION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION; CLASSIFICATION; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; PANDEMICS; SEASON;

ANTIBODIES, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; SEASONS;

EID: 84964691699     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.12.005     Document Type: Article

References (77)

1. [1] Smith, D.J., Lapedes, A.S., de Jong, J.C., Bestebroer, T.M., Rimmelzwaan, G.F., Osterhaus, A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305 (2004), 371–376.
2. [2] Koel, B.F., Burke, D.F., Bestebroer, T.M., van der Vliet, S., Zondag, G.C., Vervaet, G., et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342 (2013), 976–979.
3. [3] Skowronski, D.M., Chambers, C., Sabaiduc, S., De Serres, G., Dickinson, J.A., Winter, A.L., et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill, 20, 2015.
4. [4] Pebody, R.G., Warburton, F., Ellis, J., Andrews, N., Thompson, C., von Wissmann, B., et al. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill, 20, 2015, 21025.
5. [5] Gilca, R., Skowronski, D.M., Douville-Fradet, M., Amini, R., Boulianne, N., Rouleau, I., et al. Mid-season estimates of influenza vaccine effectiveness against influenza A(H3N2) hospitalization in the elderly in Quebec, Canada, January 2015. PLoS One, 10, 2015, e0132195.
6. [6] Herfst, S., Schrauwen, E.J., Linster, M., Chutinimitkul, S., de Wit, E., Munster, V.J., et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336 (2012), 1534–1541.
7. [7] Imai, M., Herfst, S., Sorrell, E.M., Schrauwen, E.J., Linster, M., De Graaf, M., et al. Transmission of influenza A/H5N1 viruses in mammals. Virus Res 178 (2013), 15–20.
8. [8] Linster, M., van Boheemen, S., de Graaf, M., Schrauwen, E.J., Lexmond, P., Manz, B., et al. Identification, characterization, and natural selection of mutations driving airborne transmission of A/H5N1 virus. Cell 157 (2014), 329–339.
9. [9] Russell, C.A., Fonville, J.M., Brown, A.E., Burke, D.F., Smith, D.L., James, S.L., et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 336 (2012), 1541–1547.
10. [10] Yang, Z.F., Mok, C.K., Peiris, J.S., Zhong, N.S., Human infection with a novel avian influenza A(H5N6) virus. N Engl J Med 373 (2015), 487–489.
11. [11] Yuan, J., Zhang, L., Kan, X., Jiang, L., Yang, J., Guo, Z., et al. Origin and molecular characteristics of a novel 2013 avian influenza A(H6N1) virus causing human infection in Taiwan. Clin Infect Dis 57 (2013), 1367–1368.
12. [12] Tweed, S.A., Skowronski, D.M., David, S.T., Larder, A., Petric, M., Lees, W., et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 10 (2004), 2196–2199.
13. [13] Fouchier, R.A., Schneeberger, P.M., Rozendaal, F.W., Broekman, J.M., Kemink, S.A., Munster, V., et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 101 (2004), 1356–1361.
14. [14] Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368 (2013), 1888–1897.
15. [15] Butt, K.M., Smith, G.J., Chen, H., Zhang, L.J., Leung, Y.H., Xu, K.M., et al. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 43 (2005), 5760–5767.
16. [16] Chen, H., Yuan, H., Gao, R., Zhang, J., Wang, D., Xiong, Y., et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 383 (2014), 714–721.
17. [17] Skowronski, D.M., Janjua, N.Z., De Serres, G., Hottes, T.S., Dickinson, J.A., Crowcroft, N., et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ, 342, 2011, c7297.
18. [18] Kotsimbos, T., Waterer, G., Jenkins, C., Kelly, P.M., Cheng, A., Hancox, R.J., et al. Influenza A/H1N1_09: Australia and New Zealand's winter of discontent. Am J Respir Crit Care Med 181 (2010), 300–306.
19. [19] Schotsaert, M., De Filette, M., Fiers, W., Saelens, X., Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8 (2009), 499–508.
20. [20] Wan, H., Gao, J., Xu, K., Chen, H., Couzens, L.K., Rivers, K.H., et al. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol 87 (2013), 9290–9300.
21. [21] Wohlbold, T.J., Nachbagauer, R., Xu, H., Tan, G.S., Hirsh, A., Brokstad, K.A., et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio, 6, 2015, e02556.
22. [22] Liu, W.C., Lin, C.Y., Tsou, Y.T., Jan, J.T., Wu, S.C., Cross-reactive neuraminidase-inhibiting antibodies elicited by immunization with recombinant neuraminidase proteins of H5N1 and pandemic H1N1 influenza A viruses. J Virol 89 (2015), 7224–7234.
23. [23] Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3 (2013), 521–530.
24. [24] Marcelin, G., DuBois, R., Rubrum, A., Russell, C.J., McElhaney, J.E., Webby, R.J., A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS One, 6, 2011, e26335.
25. [25] El Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186 (2011), 1022–1031.
26. [26] Jegerlehner, A., Schmitz, N., Storni, T., Bachmann, M.F., Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172 (2004), 5598–5605.
27. [27] Carragher, D.M., Kaminski, D.A., Moquin, A., Hartson, L., Randall, T.D., A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181 (2008), 4168–4176.
28. [28] LaMere, M.W., Lam, H.T., Moquin, A., Haynes, L., Lund, F.E., Randall, T.D., et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186 (2011), 4331–4339.
29. [29] Bodewes, R., Geelhoed-Mieras, M.M., Wrammert, J., Ahmed, R., Wilson, P.C., Fouchier, R.A., et al. In vitro assessment of the immunological significance of a human monoclonal antibody directed to the influenza a virus nucleoprotein. Clin Vaccine Immunol 20 (2013), 1333–1337.
30. [30] Schulman, J.L., Khakpour, M., Kilbourne, E.D., Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2 (1968), 778–786.
31. [31] Johansson, B.E., Bucher, D.J., Kilbourne, E.D., Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 63 (1989), 1239–1246.
32. [32] Couch, R.B., Atmar, R.L., Keitel, W.A., Quarles, J.M., Wells, J., Arden, N., et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 31 (2012), 190–195.
33. [33] Sandbulte, M.R., Jimenez, G.S., Boon, A.C., Smith, L.R., Treanor, J.J., Webby, R.J., Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med, 4, 2007, e59.
34. [34] Okuno, Y., Isegawa, Y., Sasao, F., Ueda, S., A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67 (1993), 2552–2558.
35. [35] Dreyfus, C., Laursen, N.S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D.C., et al. Highly conserved protective epitopes on influenza B viruses. Science 337 (2012), 1343–1348.
36. [36] DiLillo, D.J., Tan, G.S., Palese, P., Ravetch, J.V., Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20 (2014), 143–151.
37. [37] Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio, 1, 2010.
38. [38] Lu, Y., Welsh, J.P., Swartz, J.R., Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci U S A 111 (2014), 125–130.
39. [39] Eggink, D., Goff, P.H., Palese, P., Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J Virol 88 (2014), 699–704.
40. [40] Margine, I., Krammer, F., Hai, R., Heaton, N.S., Tan, G.S., Andrews, S.A., et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87 (2013), 10435–10446.
41. [41] Altenburg, A.F., Rimmelzwaan, G.F., de Vries, R.D., Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine 33 (2015), 500–506.
42. [42] Hillaire, M.L.B., van Trierum, S.E., Kreijtz, J.H.C.M., Bodewes, R., Geelhoed-Mieras, M.M., Nieuwkoop, N.J., et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 92 (2011), 2339–2349.
43. [43] Kreijtz, J.H., Bodewes, R., van Amerongen, G., Kuiken, T., Fouchier, R.A., Osterhaus, A.D., et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25 (2007), 612–620.
44. [44] Kreijtz, J.H.C.M., Bodewes, R., van den Brand, J.M.A., de Mutsert, G., Baas, C., van Amerongen, G., et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27 (2009), 4983–4989.
45. [45] Weinfurter, J.T., Brunner, K., Capuano, S.V. 3rd, Li, C., Broman, K.W., Kawaoka, Y., et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog, 7, 2011, e1002381.
46. [46] Gotch, F., McMichael, A., Smith, G., Moss, B., Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J Exp Med 165 (1987), 408–416.
47. [47] Lee, L.Y., Ha do, L.A., Simmons, C., de Jong, M.D., Chau, N.V., Schumacher, R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118 (2008), 3478–3490.
48. [48] Zweerink, H.J., Courtneidge, S.A., Skehel, J.J., Crumpton, M.J., Askonas, B.A., Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses. Nature 267 (1977), 354–356.
49. [49] van de Sandt, C.E., Kreijtz, J.H., de Mutsert, G., Geelhoed-Mieras, M.M., Hillaire, M.L., Vogelzang-van Trierum, S.E., et al. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol 88 (2014), 1684–1693.
50. [50] Hillaire, M.L., Vogelzang-van Trierum, S.E., Kreijtz, J.H., de Mutsert, G., Fouchier, R.A., Osterhaus, A.D., et al. Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses. J Gen Virol 94 (2013), 583–592.
51. [51] Hillaire, M.L., van Trierum, S.E., Bodewes, R., van Baalen, C.A., van Binnendijk, R.S., Koopmans, M.P., et al. Characterization of the human CD8(+) T cell response following infection with 2009 pandemic influenza H1N1 virus. J Virol 85 (2011), 12057–12061.
52. + T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162 (1999), 7578–7583.
53. [53] Kreijtz, J.H., de Mutsert, G., van Baalen, C.A., Fouchier, R.A., Osterhaus, A.D., Rimmelzwaan, G.F., Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82 (2008), 5161–5166.
54. [54] Tu, W., Mao, H., Zheng, J., Liu, Y., Chiu, S.S., Qin, G., et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 84 (2010), 6527–6535.
55. [55] McMichael, A.J., Gotch, F.M., Noble, G.R., Beare, P.A., Cytotoxic T-cell immunity to influenza. N Engl J Med 309 (1983), 13–17.
56. [56] Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19 (2013), 1305–1312.
57. [57] Hayward, A.C., Wang, L., Goonetilleke, N., Fragaszy, E.B., Bermingham, A., Copas, A., et al. Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care Med 191 (2015), 1422–1431.
58. [58] Wang, Z., Wan, Y., Qiu, C., Quinones-Parra, S., Zhu, Z., Loh, L., et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells. Nat Commun, 6, 2015, 6833.
59. + T cells correlate with disease protection against influenza challenge in humans. Nat Med 18 (2012), 274–280.
60. [60] Wiersma, L.C., Rimmelzwaan, G.F., de Vries, R.D., Developing universal influenza vaccines: hitting the nail, not just on the head. Vaccines (Basel) 3 (2015), 239–262.
61. [61] de Vries, R.D., Altenburg, A.F., Rimmelzwaan, G.F., Universal influenza vaccines, science fiction or soon reality?. Expert Rev Vaccines 14 (2015), 1299–1301.
62. [62] Schwartzman, L.M., Cathcart, A.L., Pujanauski, L.M., Qi, L., Kash, J.C., Taubenberger, J.K., An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus. MBio, 6, 2015, e01044.
63. [63] Hessel, A., Savidis-Dacho, H., Coulibaly, S., Portsmouth, D., Kreil, T.R., Crowe, B.A., et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One, 9, 2014, e88340.
64. [64] Antrobus, R.D., Lillie, P.J., Berthoud, T.K., Spencer, A.J., McLaren, J.E., Ladell, K., et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One, 7, 2012, e48322.
65. + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52 (2011), 1–7.
66. [66] Lillie, P.J., Berthoud, T.K., Powell, T.J., Lambe, T., Mullarkey, C., Spencer, A.J., et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 55 (2012), 19–25.
67. [67] de Vries, R.D., De Gruyter, H.L., Bestebroer, T.M., Pronk, M., Fouchier, R.A., Osterhaus, A.D., et al. Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine. Emerg Infect Dis 21 (2015), 1086–1088.
68. [68] Kreijtz, J.H., Goeijenbier, M., Moesker, F.M., van den Dries, L., Goeijenbier, S., De Gruyter, H.L., et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 14 (2014), 1196–1207.
69. [69] Kreijtz, J.H., Suezer, Y., de Mutsert, G., van Amerongen, G., Schwantes, A., van den Brand, J.M., et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One, 4, 2009, e7790.
70. [70] Kreijtz, J.H., Suezer, Y., de Mutsert, G., van den Brand, J.M., van Amerongen, G., Schnierle, B.S., et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 199 (2009), 405–413.
71. [71] Kreijtz, J.H., Suezer, Y., van Amerongen, G., de Mutsert, G., Schnierle, B.S., Wood, J.M., et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 195 (2007), 1598–1606.
72. [72] Girard, M.P., Tam, J.S., Pervikov, Y., Katz, J.M., Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24–26 January 2013. Vaccine 31 (2013), 3766–3771.
73. [73] Hughes, B., Hayden, F., Perikov, Y., Hombach, J., Tam, J.S., Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16–17 November 2011. Vaccine 30 (2012), 6612–6622.
74. [74] Stephenson, I., Hayden, F., Osterhaus, A., Howard, W., Pervikov, Y., Palkonyay, L., et al. Report of the fourth meeting on ‘Influenza vaccines that induce broad spectrum and long-lasting immune responses’, World Health Organization and Wellcome Trust, London, United Kingdom, 9–10 November 2009. Vaccine 28 (2010), 3875–3882.
75. [75] Price, G.E., Soboleski, M.R., Lo, C.Y., Misplon, J.A., Quirion, M.R., Houser, K.V., et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One, 5, 2010, e13162.
76. [76] Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.J., Kanekiyo, M., Kong, W.P., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21 (2015), 1065–1070.
77. [77] Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M., Zhu, X., Hoffman, R.M., et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349:6254 (2015), 1301–1306.